4yr
Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34411338/
Programmed death-ligand 1 (PD-L1)-mediated resistance has become a great challenge for tumor treatment. Cisplatin increased tumor PD-L1 expression, promoted chemotherapy resistance. Interferon-γ (IFN-γ)-induced PD-L1 expression might facilitate immunotherapy resistance. Methylseleninic acid (MSeA), a selenium (Se) compound, offered superior cancer chemo-preventive activities and enhanced tumor sensitivity to diverse chemotherapeutic drugs.
• Conclusion/Relevance: “Our findings, for the first time, demonstrated that MSeA is a potential agent to overcome PD-L1-mediated chemotherapy and immunotherapy resistance. Such information might have potential clinical implications for prostate and lung cancer treatment.”
• In previous studies, the selenium compound methylseleninic acid (MSeA) has demonstrated enhanced cancer chemo-preventive activities and enhanced tumor sensitivity to various chemotherapies.
• In the current preclinical study involving in vitro and in vivo prostate and lung cancer models, investigators assessed the effects of MSeA on the PD-L1-mediated resistance. They observed that MSeA substantially inhibited cisplatin-induced PD-L1 expression by means of inhibiting protein kinase B phosphorylation. Consequently, cisplatin cytotoxicity in prostate and lung cancer cell models was increased.
• “It has been reported that IFN-γ-induced PD-L1 expression may be associated with immunotherapy resistance, which indicates that inhibiting IFN-γ-induced PD-L1 expression can potentiate the effects of immunotherapy,” wrote the authors. “Therefore, we hypothesized that MSeA might overcome immunotherapy resistance, however, there is no data to support this hypothesis in this study.”